Gastroenteropancreatic neuroendocrine tumor (GEP-NET) is a group of rare tumors that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These tumors are capable of producing various hormones and biologically active substances, which can cause a variety of clinical manifestations. The classification of GEP-NETs includes functional (hormone-producing) and non-functional tumors, each of which has its own characteristic symptoms, diagnostic methods and treatment approaches. These tumors can vary from poorly differentiated to highly differentiated, differing in their aggressiveness and prognosis. Diagnosis of GEP-NETs is often difficult due to the variety of clinical symptoms and the need for differential diagnosis with other diseases of the gastrointestinal tract.
History of the disease and interesting historical facts
The history of the study of gastroenteropancreatic neuroendocrine tumors dates back to the early 20th century. The first mention of neuroendocrine tumors dates back to the works of Russian and European pathologists, who described various morphological forms of these formations. In the 1940s, neuropathologists began to classify neuroendocrine cells as separate components of the endocrine system. In the 1970s, significant progress was made in understanding the role of these cells in the body, thanks to advances in immunohistochemistry and biochemistry. With the advent of more modern imaging techniques and molecular diagnostics, it became possible to diagnose and treat GEP-NETs much more effectively, which increased the survival rate of patients with this pathology. Interestingly, in some cases, neuroendocrine tumors can manifest as syndromes associated with excess of certain hormones, such as insulin or gastrin, leading to specific clinical situations.
Epidemiology
According to current statistics, gastroenteropancreatic neuroendocrine tumors are relatively rare, with an incidence of approximately 0.5-2 cases per 100,000 population per year. However, there has been a trend toward an increase in the number of reported cases in recent decades, which may be due to both improved diagnostics and a real increase in incidence. GEP-NETs are most common in people aged 40-70 years, with men being affected somewhat more often than women. Specific tumor types, such as insulinoma, have their own statistical characteristics, for example, insulinoma is more common in people aged 40-60 years and causes severe metabolic disorders, making clinical manifestations and diagnosis difficult. The main regions with high incidence rates include North America and Europe, while in developing countries the incidence remains significantly lower.
Genetic predisposition to this disease
Genetic predisposition plays an important role in the development of gastroenteropancreatic neuroendocrine tumors. Among the genes involved are MEN1, which is associated with multiple endocrine neoplasia type 1, as well as TP53, RET, and NF1 genes. Patients with MEN1 syndrome are at high risk of developing pancreatic neuroendocrine tumors, the incidence of which can reach 30-80% during life. It has also been found that some patients have mutations in the DAXX gene, which may indicate a more aggressive course of the disease. Genetic predisposition can be both hereditary and spontaneous, which makes the diagnostic and screening strategy no less important for patients with a family history of GEP-NET. Importantly, early diagnosis and possible genetic testing can help in identifying risk groups and timely initiation of preventive measures.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of gastroenteropancreatic neuroendocrine tumors. Among the physical factors are:
- Age: The incidence increases with age, especially in people over 40 years of age.
- Gender: Men are more likely to be affected by GEP-NET than women.
Chemical risk factors include:
- Long-term exposure to certain carcinogens, such as formaldehyde and benzene.
- Chemicals used in production may influence the development of tumors.
Other factors associated with GEP-NET include:
- Having a family history of neuroendocrine tumors.
- The presence of other endocrine diseases or syndromes, such as diabetes or acromegaly.
The extent to which the above factors influence the development of GEP-NET requires further study, but their presence may serve as a signal for more careful monitoring and early diagnosis.
Diagnosis of this disease
Diagnosis of gastroenteropancreatic neuroendocrine tumors requires a multi-step approach and may involve several methods. The main symptoms caused by GEP-NETs can be varied and often depend on what hormones the tumor produces. Functional tumors are characterized by specific syndromes:
- Insulinoma: hypoglycemia, sweating, dizziness.
- Gastrinoma: peptic ulcer, high acidity.
Laboratory tests include:
- Determination of levels of specific biomarkers such as C-reactive protein and neuroendocrine hormones.
- Complete blood count and biochemical analysis.
Radiological examinations such as CT, MRI and PET allow to visualize the tumors and to estimate their size and extent. It is also important to perform differential diagnosis to exclude other diseases with similar symptoms such as chronic pancreatitis or pacific gastrofibrosis. Finally, biopsy may be necessary for final verification of the diagnosis and assessment of the histological grade of the tumor.
Treatment
Treatment of gastroenteropancreatic neuroendocrine tumors is complex and usually involves a combination of several methods. General treatment may include advice on lifestyle changes, improved nutrition, and symptom control. Pharmacological treatment may include the use of hormone modulators to reduce symptoms, such as proton pump inhibitors for gastrinomas or insulin-lowering drugs for insulinoma. Surgery is the most effective method for localized tumors. This may include tumor resection or pancreaticoduodenectomy. In cases of tumor metastasis to other organs, chemotherapy or radiotherapy may be required. Immunotherapy and targeted drugs are also considered as promising directions in the treatment of GEP-NETs.
List of medications used to treat this disease
The list of drugs used to treat gastroenteropancreatic neuroendocrine tumors includes:
- Sandostatin (Octreotide) - to control symptoms associated with excess hormone production;
- Lanreotide is an analogue of octreotide for controlling hormone levels;
- Liver tyrosine before injuries (sulfasalazine) - for complex treatment;
- Systemic chemotherapy drugs such as temozolomide and capecitabine;
- Targeted drugs, such as eurolimus, which can be used for advanced tumors.
Disease monitoring
Monitoring of gastroenteropancreatic neuroendocrine tumors is a key aspect of disease management. Monitoring steps include regular examinations, assessment of biomarker levels, and radiological examinations to evaluate the tumor and detect recurrence. Prognosis depends on many factors: tumor aggressiveness, presence of metastases, and the patient’s general condition. Complications may vary depending on the tumor type and may include endocrine disorders, metabolic disorders, and treatment-related complications. Patients should be closely monitored to adjust treatment if new symptoms occur or the condition worsens.
Age-related features of the disease
Gastroenteropancreatic neuroendocrine tumors may have different manifestations depending on the age group of the patients. Younger patients (under 40 years) often have more aggressive forms of tumors that may progress more rapidly. In adults, insulinoma and gastrinoma may manifest themselves more significantly, given metabolic and environmental factors, making their symptoms more pronounced. In older people, tumors often have a more indolent course, but a high level of comorbidity can complicate diagnosis and treatment. In general, the age of the patient influences the choice of treatment methods and approaches to monitoring the condition.
Questions and Answers
- What is gastroenteropancreatic neuroendocrine tumor? These are a group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas that can produce hormones and cause a variety of symptoms.
- What are the main symptoms of GEP-NET? Symptoms may vary depending on the function of the tumor, including hypoglycemia, ulcers, and other endocrine disorders.
- What methods exist for diagnosing this disease? Diagnosis includes laboratory tests, imaging methods (CT, MRI), and biopsy to confirm the diagnosis.
- What treatment is recommended for GEP-NET? Treatment can be surgical, pharmacological or combined, depending on the stage of the disease and the patient's condition.
- What is the likelihood of relapse after treatment? The likelihood of recurrence varies depending on the type and stage of the tumor, so regular monitoring of the condition is necessary if the risk of recurrence is high.
Advice from Dr. Oleg Korzhikov
In his recommendations, Dr. Oleg Korzhikov emphasizes the importance of early diagnostics and a comprehensive approach to the treatment of gastroenteropancreatic neuroendocrine tumors. "Pay attention to any changes in your health, especially if they are accompanied by symptoms associated with the endocrine system. Do not delay in contacting a specialist if new symptoms appear, such as frequent headaches, sudden weight changes, or digestive problems," the doctor advises. The use of modern diagnostic methods and regular examinations can significantly improve the outcome of the disease.
